Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Up 37.1% in December

Avalon GloboCare Corp. (NASDAQ:ALBT) was the target of a large increase in short interest in December. As of December 31st, there was short interest totaling 111,024 shares, an increase of 37.1% from the December 15th total of 80,987 shares. Approximately 2.9% of the company’s stock are short sold. Based on an average daily volume of 145,299 shares, the short-interest ratio is currently 0.8 days. Based on an average daily volume of 145,299 shares, the short-interest ratio is currently 0.8 days. Approximately 2.9% of the company’s stock are short sold.

Avalon GloboCare Price Performance

NASDAQ ALBT opened at $1.17 on Friday. The company has a market capitalization of $4.97 million, a price-to-earnings ratio of -0.33 and a beta of -0.09. Avalon GloboCare has a 12 month low of $0.88 and a 12 month high of $11.66. The company’s fifty day moving average price is $1.37 and its two-hundred day moving average price is $2.00.

Avalon GloboCare (NASDAQ:ALBT) last released its earnings results on Friday, November 14th. The company reported ($0.06) earnings per share for the quarter. The firm had revenue of $0.35 million for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Avalon GloboCare in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.